Home Newsfeeds Swissmedic Approves Bivalent COVID-19 Booster Vaccine From Pfizer

Swissmedic Approves Bivalent COVID-19 Booster Vaccine From Pfizer

-Reuters

byBill Haddad

October 10, 2022

1 minute read

-Reuters

Biomea Fusion Doses First Patient In Phase I/Ib Clinical Trial Of BMF-219 In KRAS Mutant Solid Tumors

By Benzinga Newsdesk

January 17, 9:11 AM

BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) A pan-KRAS inhibitor

BMEA

Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth

By Vandana Singh

September 14, 1:53 PM

Bristol-Myers Squibb & Co (NYSE: BMY) announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted protein

BMY

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

By Vandana Singh

June 3, 10:27 AM

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3 trials are now underway for melanoma and non-small cell lung cancer.

MRK

What’s Going On With VinFast Shares After Reaffirming Outlook Of 100,000 EV Deliveries?

By Nabaparna Bhattacharya

April 17, 8:17 AM

VinFast shares rise after reporting Q1 earnings, with 100,000 EV delivery target for FY24 reaffirmed amidst global expansion plans.

VFS

Swissmedic Approves Bivalent COVID-19 Booster Vaccine From Pfizer

Related Posts

Biomea Fusion Doses First Patient In Phase I/Ib Clinical Trial Of BMF-219 In KRAS Mutant Solid Tumors

Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

What’s Going On With VinFast Shares After Reaffirming Outlook Of 100,000 EV Deliveries?